ABC-Scores for Reduction of Stroke and Mortality in Atrial Fibrillation - The ABC-AF Study
- Conditions
- Atrial Fibrillation
- Interventions
- Other: ABC score guided therapyOther: Standard care
- Registration Number
- NCT03753490
- Lead Sponsor
- Uppsala University
- Brief Summary
The primary study objective is to evaluate if personalized treatment by decision support, based on the biomarker-based risk prediction (ABC-scores) guided strategy, reduces the occurrence of the composite outcome of stroke or death in patients with atrial fibrillation. Approximately 6500 patients will be randomized 1:1 to ABC risk score guided therapy or standard care.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 3933
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ABC score guided therapy ABC score guided therapy Individual treatment recommendations based on the ABC-scores for stroke and bleeding. Standard care Standard care Management according to local practice, national and international guidelines.
- Primary Outcome Measures
Name Time Method Composite of Stroke or Death From the date of enrolment through study completion, minimum follow-up 2 years.
- Secondary Outcome Measures
Name Time Method Stroke From the date of enrolment through study completion, minimum follow-up 2 years. Death From the date of enrolment through study completion, minimum follow-up 2 years. Major Bleeding From the date of enrolment through study completion, minimum follow-up 2 years. Myocardial Infarction From the date of enrolment through study completion, minimum follow-up 2 years. Heart Failure From the date of enrolment through study completion, minimum follow-up 2 years. Health Economics From the date of enrolment through study completion, minimum follow-up 2 years. Mean differences in health care cost, and 2-year quality-adjusted survival based on EuroQol-5D-5L between the treatment groups, combined into an incremental cost-effectiveness ratio.
Trial Locations
- Locations (1)
Uppsala University Hospital
πΈπͺUppsala, Sweden